Text Size

Mapracorat, a selective glucocorticoid receptor agonist, upregulates RelB, an anti-inflammatory nuclear factor-kappaB protein, in human ocular cells

Spinelli S.L., Xi X., McMillan D.H., Woeller C.F., Richardson M.E., Cavet M.E., Zhang J.-Z., Feldon S.E., Phipps R.P.


  • 2014
  • Experimental Eye Research
View publication
  • Therapeutic Area

    Front of the eye (FOTE)

  • Categories

    Clinical development

  • Affiliations

    Department of Pathology and Laboratory Medicine, University of Rochester School of Medicine and Dentistry, Rochester, NY, United States; Department of Ophthalmology, University of Rochester School of Medicine and Dentistry, Rochester, NY, United States; University of Rochester School of Medicine and Dentistry, Rochester, NY, United States; Flaum Eye Institute, University of Rochester School of Medicine and Dentistry, Rochester, NY, United States; Global Pharmaceutical R and D, Bausch and Lomb, Inc., Rochester, NY, United States; Department of Pathology, University of Vermont, Burlington, VT, United States; Preclinical Development, Santen Inc., Emeryville, CA, United States

Related Publications

Burden of Vernal Keratoconjunctivitis in the United States: A Retrospective Claims Database Analysis

Koo E.B.; Yu T.M.; Layton A.J.; Babineaux S.; Fung S.


Review of clinical outcomes of a cationic emulsion tear substitute in patients with dry eye disease

Labetoulle M, Garhöfer G, Ismail D, Garrigue JS, Amrane M, Guillon M, Aragona P, Baudouin C.


Epinastine Cream: A Novel Once-Daily Therapeutic Agent for Allergic Conjunctivitis

Ogura N., Fujisawa K., Kato M.


Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022